Reports
1 reportQuarterly reports, annual reports and year-end reports from Sigrid Therapeutics, newest first.
Sigrid Therapeutics: a clearer technology model in Q1 2026
Sales increased 97 per cent compared with Q1 2025. The board approved a strategic pivot towards a clearer technology model centred on SiPore. The first formal out-licensing to an adjacent vertical got under way operationally during the quarter.
Sigrid Therapeutics in the catalogue
The company's own page has the share price, valuation, owners and the reports published for trading.
Go to Sigrid TherapeuticsOther news about Sigrid Therapeutics
7 postsEverything we have written about Sigrid Therapeutics, newest first. The reports stand on their own at the top and the rest of the news below them — acquisitions, share issues, partnerships and what the company itself has announced. You will find the share price, valuation and company data on the company's own page.
Sigrid Therapeutics 2025: revenue up 648 per cent and loss down 49 per cent
Sigrid Therapeutics has submitted its annual report for 2025. Net sales rose to 12.8 MSEK, the loss narrowed to 22.1 MSEK and the equity ratio strengthened to 78 per cent. During the year the company entered into an exclusive global licensing and research collaboration.
Sigrid Therapeutics H1 2026 – sales up 53 per cent and the SHINE study published
Sigrid Therapeutics has published its shareholder report for the first half of 2026. Sales rose 53 per cent compared with the same period last year, the clinical SHINE study was published in the Lancet family's eClinicalMedicine and CE marking remains on…
Sigrid Therapeutics launches on Fullscript
The company’s first large-scale distribution platform to healthcare providers in the US. Two products. North America’s leading healthcare provider platform.
Sigrid raises capital – Launches Ozempic challenger
Swedish medtech company Sigrid Therapeutics has raised SEK 45 million in a new share issue to increase its market presence in the US and prepare the launch of Carb fence – an over-the-counter weight-loss product described as an alternative to the drug…
Sigrid Therapeutics Receives Notice of Allowance for US Patent Covering Novel Porous Silica Materials
Stockholm, 8 September 2025 – Sigrid Therapeutics announces that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for the company's patent application US2022135411A1, “Highly Structured Porous Silica Materials and Biological Uses Thereof”.
Kronans Apotek to Launch SIGRID Stabiliser in 100 Pharmacies Following Record Online Sales
SIGRID Stabiliser to Launch in up to 100 Kronans Apotek Stores Across Sweden This Fall
SIGRID Stabiliser – Record online sales at Kronans Apotek lead to in-store launch this autumn
Stockholm, 27 August 2025 – After a very successful online premiere earlier this year, Sigrid Therapeutics and Kronans Apotek are taking the next step: from autumn 2025, SIGRID Stabiliser will be on the shelves in up to 100 of Kronans' physical pharmacies around…
